127 related articles for article (PubMed ID: 19605761)
1. Passive diffusion of naltrexone into human and animal cells and upregulation of cell proliferation.
Cheng F; McLaughlin PJ; Banks WA; Zagon IS
Am J Physiol Regul Integr Comp Physiol; 2009 Sep; 297(3):R844-52. PubMed ID: 19605761
[TBL] [Abstract][Full Text] [Related]
2. Internalization of the opioid growth factor, [Met5]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation.
Cheng F; McLaughlin PJ; Banks WA; Zagon IS
Am J Physiol Regul Integr Comp Physiol; 2010 Sep; 299(3):R774-85. PubMed ID: 20592180
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the opioid growth factor receptor in human cancers alter receptor function.
Kren NP; Zagon IS; McLaughlin PJ
Int J Mol Med; 2015 Jul; 36(1):289-93. PubMed ID: 26005722
[TBL] [Abstract][Full Text] [Related]
4. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium.
Zagon IS; Ruth TB; McLaughlin PJ
Anat Rec A Discov Mol Cell Evol Biol; 2005 Jan; 282(1):24-37. PubMed ID: 15584033
[TBL] [Abstract][Full Text] [Related]
5. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2011 Sep; 236(9):1036-50. PubMed ID: 21807817
[TBL] [Abstract][Full Text] [Related]
6. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
Immonen JA; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2014 Oct; 239(10):1300-9. PubMed ID: 25030485
[TBL] [Abstract][Full Text] [Related]
7. Opioids and differentiation in human cancer cells.
Zagon IS; McLaughlin PJ
Neuropeptides; 2005 Oct; 39(5):495-505. PubMed ID: 16169076
[TBL] [Abstract][Full Text] [Related]
8. Reepithelialization of the human cornea is regulated by endogenous opioids.
Zagon IS; Sassani JW; McLaughlin PJ
Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):73-81. PubMed ID: 10634604
[TBL] [Abstract][Full Text] [Related]
9. Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells.
Zagon IS; Rahn KA; McLaughlin PJ
Neuropeptides; 2007 Dec; 41(6):441-52. PubMed ID: 17910895
[TBL] [Abstract][Full Text] [Related]
10. Opioid growth factor regulates the cell cycle of human neoplasias.
Zagon IS; Roesener CD; Verderame MF; Ohlsson-Wilhelm BM; Levin RJ; McLaughlin PJ
Int J Oncol; 2000 Nov; 17(5):1053-61. PubMed ID: 11029512
[TBL] [Abstract][Full Text] [Related]
11. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.
Zagon IS; McLaughlin PJ
Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586
[TBL] [Abstract][Full Text] [Related]
12. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.
Zagon IS; Donahue RN; McLaughlin PJ
Am J Physiol Regul Integr Comp Physiol; 2009 Oct; 297(4):R1154-61. PubMed ID: 19675283
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.
Zagon IS; Verderame MF; Hankins J; McLaughlin PJ
Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors.
McLaughlin PJ; Rogosnitzky M; Zagon IS
Exp Biol Med (Maywood); 2010 Nov; 235(11):1292-9. PubMed ID: 20975079
[TBL] [Abstract][Full Text] [Related]
15. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.
McLaughlin PJ; Sassani JW; Klocek MS; Zagon IS
Brain Res Bull; 2010 Feb; 81(2-3):236-47. PubMed ID: 19683562
[TBL] [Abstract][Full Text] [Related]
16. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.
Donahue RN; McLaughlin PJ; Zagon IS
Am J Physiol Regul Integr Comp Physiol; 2009 Jun; 296(6):R1716-25. PubMed ID: 19297547
[TBL] [Abstract][Full Text] [Related]
17. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
Donahue RN; McLaughlin PJ; Zagon IS
Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
[TBL] [Abstract][Full Text] [Related]
18. The opioid growth factor, [Met5]-enkephalin, inhibits DNA synthesis during recornification of mouse tail skin.
Wilson RP; McLaughlin PJ; Lang CM; Zagon IS
Cell Prolif; 2000 Apr; 33(2):63-73. PubMed ID: 10845251
[TBL] [Abstract][Full Text] [Related]
19. Regulation of cell proliferation by the opioid growth factor receptor is dependent on karyopherin beta and Ran for nucleocytoplasmic trafficking.
Cheng F; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2010 Sep; 235(9):1093-101. PubMed ID: 20705629
[TBL] [Abstract][Full Text] [Related]
20. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2011 Jul; 236(7):883-95. PubMed ID: 21685240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
